Omar Mamlouk

Jul 12, 2024 | digitalcommons.library.tmc.edu | Ala Abudayyeh |Liye Suo |Heather Lin |Omar Mamlouk

AbstractBackground: Immune-related adverse events are a management challenge in patients receiving immune checkpoint inhibitors (ICIs). The most common renal immune-related adverse event, acute interstitial nephritis (AIN), is associated with patient morbidity and mortality. AIN, characterized by infiltration of renal tissue with immune cells, may be analogous to kidney transplant rejection.